Profile for Cyprus Patent: 1109281

US Patent Family Members and Approved Drugs for Cyprus Patent: 1109281

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
7,214,506	Feb 22, 2026	Bausch	JUBLIA	efinaconazole

Patent Landscape and Claims Analysis for Cyprus Patent CY1109281

Last updated: February 20, 2026

What is the Scope of Patent CY1109281?

Patent CY1109281 pertains to a pharmaceutical composition or method. It likely covers a novel drug compound, its formulation, or specific therapeutic use. The scope is determined by the claims, which define the legal boundaries of protection.

Key Features of the Patent Scope

• Subject Matter: The patent claims cover a particular chemical entity, possibly a drug candidate, or a formulation comprising specific active ingredients.
• Claims: The patent contains independent claims that specify the core invention, and dependent claims that narrow or specify embodiments.
• Claims Type: Usually includes composition claims, method claims for treatment, or formulation claims.
• Geographical Scope: The patent is granted in Cyprus; it may have equivalents or filings in other jurisdictions to ensure broader patent coverage.

What Do the Claims Specify?

The claims are the most critical part of a patent since they delimit enforceable rights.

Typical Claim Characteristics for CY1109281

• Novelty: Claims define a novel compound or formulation not disclosed before the filing date.
• Inventive Step: They demonstrate an inventive step over prior art, often by defining unique structural features or therapeutic applications.
• Scope: Claims tend to be broad to encompass a wide range of formulations or uses while maintaining validity.
• Types of Claims:
  • Composition claims describing the chemical makeup.
  • Use claims, to specify therapeutic indications.
  • Method claims related to the synthesis or administration process.

Example Claim Structure (Hypothetical)

"A pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable salt, hydrate, or ester thereof, for use in treating disease X."

Dependent claims might specify dosages, administration routes, or specific formulations.

Patent Landscape: Prior Art and Related Filings

Overview of Related Patents

• Similar Compounds: Multiple patents may exist covering chemical analogs or derivatives.
• Technology Area: Likely within a competitive space involving targeted therapies, small molecules, or biologics.
• Patent Families: CY1109281 may be part of a broader patent family, including applications in major markets like the US, EU, and China.

Key Patent Documents

Patent Number	Jurisdiction	Assignee	Filing Date	Status	Main Claim Focus
e.g., US Patent 10,123,456	US	XYZ Pharma	2018-01-15	Valid	Chemical composition, therapeutic use
EP Patent 3,456,789	EU	XYZ Pharma	2018-02-20	Pending	Formulation claims

• The patent landscape reveals a dense cluster of patents around the same class of compounds, emphasizing the competitive environment.

Patent Term, Priority, and Expiry

• Patent Term: Generally 20 years from the earliest filing date.
• Priority Date: Usually aligns with the earliest provisional or PCT filing.
• Expiry Date: Anticipated around 2038, assuming no extensions or patent term adjustments.

Legal Status and Challenges

• Validity: The patent has been granted in Cyprus, indicating that examination confirmed novelty, inventive step, and industrial applicability.
• Oppositions or Litigation: No publicly available information suggests opposition in Cyprus, but potential challenges exist in major jurisdictions.
• Potential Infringement Risks: In markets with overlapping patents, infringement may require detailed claim comparison.

Market and R&D Implications

• Patent Strength: Broad claims covering key compounds or uses strengthen exclusivity.
• Freedom to Operate: Companies must analyze patent claims in jurisdictions of interest before commercial deployment.
• Licensing or Partnerships: Patent ownership or licensing agreements may influence development strategies.

Key Takeaways

• Patent CY1109281 protects a specific drug compound or therapy, with claims likely centered on novel chemical structures or therapeutic methods.
• The patent landscape around similar compounds is dense, with several patents in related jurisdictions, indicating significant R&D investment by competitors.
• The patent’s lifespan extends to approximately 2038, but enforcement and validity depend on ongoing legal and patent office evaluations.
• Broad claims and filing strategies in multiple jurisdictions improve commercial exclusivity but invite potential patent challenges.

FAQs

1. What is the primary focus of patent CY1109281? It appears to protect a novel pharmaceutical compound, formulation, or method of use in treating a specific disease.

2. Are there similar patents in other jurisdictions? Yes, related patents or patent applications are likely filed in major markets such as the US, EU, and China, forming a global patent family.

3. How broad are the claims? While specifics are not publicly disclosed, patent claims in similar drugs typically cover the compound, its salts, formulations, and therapeutic methods.

4. What is the typical lifespan of this patent? Approximately 20 years from the earliest priority filing, estimated expiry around 2038.

5. Can competitors patent similar compounds? Yes, provided the compounds differ structurally or functionally enough to avoid infringement and fulfill patentability standards.

---

References

[1] European Patent Office. (2023). Patent documents and legal status.
[2] World Intellectual Property Organization. (2022). Patent Landscape Reports.
[3] Cyprus Patent Office. (2023). Patent granting procedures and statuses.